R
Ramin B. Arani
Researcher at University of Alabama at Birmingham
Publications - 13
Citations - 2447
Ramin B. Arani is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Virus & Progressive disease. The author has an hindex of 11, co-authored 13 publications receiving 2333 citations. Previous affiliations of Ramin B. Arani include Janssen Pharmaceutica.
Papers
More filters
Journal ArticleDOI
Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy
Xiping Wei,Julie M. Decker,Hongmei Liu,Zee Zhang,Ramin B. Arani,J. Michael Kilby,Michael S. Saag,Xiaoyun Wu,George M. Shaw,John C. Kappes,John C. Kappes +10 more
TL;DR: These findings provide the first evidence for the rapid emergence of clinical resistance to a novel class of HIV-1 entry inhibitors and may be relevant to future treatment strategies involving these agents.
Journal Article
A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial.
Ronald D. Alvarez,Mack N. Barnes,Jesus Gomez-Navarro,Minghui Wang,Theresa V. Strong,Waleed Arafat,Ramin B. Arani,Martin R. Johnson,Bruce L. Roberts,Gene P. Siegal,David T. Curiel +10 more
TL;DR: This study suggests that adenoviral-mediated gene therapy using an anti-erbB-2- 2-directed intrabody is feasible in the context of human ovarian cancer.
Journal ArticleDOI
Adenoviral-Mediated Suicide Gene Therapy for Ovarian Cancer
Ronald D. Alvarez,Jesus Gomez-Navarro,Minghui Wang,Mack N. Barnes,Theresa V. Strong,Ramin B. Arani,Waleed Arafat,Joseph V. Hughes,Gene P. Siegal,David T. Curiel +9 more
TL;DR: Treatment with AdHSV-TK in combination with GCV is feasible in the context of human ovarian cancer and tolerated at the dosages studied, suggesting the potential efficacy of adenoviral-mediated suicide gene therapy in women with recurrent ovarian cancer is suggested.
Journal Article
Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration.
Robert M. Conry,Muhamad B. Khazaeli,Mansoor N. Saleh,Karen O. Allen,Daunte L. Barlow,Susan E. Moore,Dayle Craig,Ramin B. Arani,Jeffrey Schlom,Albert F. LoBuglio +9 more
TL;DR: No objective clinical responses to the rV-CEA vaccine were observed among this population of patients with widely metastatic adenocarcinoma and there is no compelling reason to recommend one administration technique over the other based upon toxicity or efficacy.
Journal Article
Ionizing Radiation Improves Survival in Mice Bearing Intracranial High-Grade Gliomas Injected with Genetically Modified Herpes Simplex Virus
J D Bradley,Yasushi Kataoka,Sunil J. Advani,S M Chung,Ramin B. Arani,George Yancey Gillespie,Richard J. Whitley,James M. Markert,Bernard Roizman,Ralph R. Weichselbaum +9 more
TL;DR: The combination of virus with fractionated ionizing radiation suggests a synergistic action and results in reduced tumor volumes and longer survivals when compared with treatment with either modality alone.